Neuronostics

Neuronostics

  • 2022
  • Speaker
  • Venture

Neuronostics is a multi-award-winning start-up developing solutions for diagnosis and management of neurological conditions. Neuronostics technology uses advanced mathematical modelling and machine learning tools to create digital biomarkers that reveal the risk of neurological conditions from routinely acquired clinical data. Spun out of the University of Exeter in 2018, its first focus is on epilepsy: a condition affecting 65 million globally. Epilepsy is hard to diagnose, easy to misdiagnose and difficult to treat. It takes a year on average to confirm a case. Misdiagnosis rates can exceed 30%. 50% of people with epilepsy are not seizure free a year post-treatment. Addressing these challenges Neuronostics’ patented BioEP marker reveals the risk of future seizures from just a few seconds of apparently normal EEG. Published studies have shown that BioEP matches current clinical practice. Recent work has shown that changes in the BioEP score over time reveals medication response.

We use a selection of our own and third-party cookies on the pages of this website: Essential cookies, which are required in order to use the website; functional cookies, which provide better easy of use when using the website; performance cookies, which we use to generate aggregated data on website use and statistics; and marketing cookies, which are used to display relevant content and advertising. If you choose "ACCEPT ALL", you consent to the use of all cookies. You can accept and reject individual cookie types and revoke your consent for the future at any time at "Settings".